Stem Cell Transplantation

Pentostatin shows promise for treatment of refractory chronic GVHD in children

Published in Blood Weekly, September 11th, 2003

Pentostatin shows promise for the treatment of chronic graft-versus-host reactions in pediatric stem cell transplant recipients.

"Chronic graft-versus-host disease (cGVHD) is a major barrier to successful allogeneic stem cell transplantation," scientists in the United States explained. "Pentostatin has been used to treat cGVHD in a small series of pediatric patients."

J.D. Goldberg and colleagues described "the results of the first five pediatric patients receiving pentostatin for refractory cGVHD at Johns Hopkins Hospital."

"In this early experience, the authors saw considerable symptom response in their patients," they reported....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2003-09-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry